Valproic acid in migraine prophylaxis;Valproinsaure in der Migraneprophylaxe

Aktuelle Neurologie

Volumn 23, Issue 6, 1996, Pages 265-268

  Diener, H C ^a,b   Gendolla, A ^a   Limmroth, V ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROIC ACID;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; HUMAN; MIGRAINE; PROPHYLAXIS; SHORT SURVEY; SIDE EFFECT;

EID: 0030457619     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1017874     Document Type: Short Survey

References (19)

1. Bryant, A. E., F. E. Dreifuss: Hepatotoxicity associated with antiepileptic drug therapy. Avoidance, identification and management. CNS Drugs 4 (1995) 99-113
2. Coria, F., A. P. Sempere, J. Duarte et al.: Low-dose sodium valproate in the prophylaxis of migraine. Clin. Neuropharmacol. 17 (1994) 569-573
3. Cutrer, F. M., V. Limmroth, G. Ayata et al.: Attentuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. British J. Pharmacol. 116 (1995) 3199-3204
4. Godin, Y., L Heiner, J. Mark et al.: Effects of di-n-propylacetate, an anticonvulsive compound on GABA metabolism. J. Neurochem. 16 (1969) 869-873
5. Hering, R., A. Kuritzky: Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 12 (1992) 81-84
6. Jensen, R., T. Brinck, J. Oelsen: Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled cross over study. Neurology 44 (1994) 647-651
7. Kaube, H., H. Hoskin, P. G. Goadsby: Antimigraine compounds fail to inhibit the propagation of cortical spreading depression. Eur. J. Neurol. (Vol.) (1994) 141-146
8. Kondo, E., H. Kiyama, T. Araki et al.: Coexpression of GABA(A) receptor gamma 1 and gamma 2 subunits in the rat trigeminal ganglion. Mol. Brain Res. 21 (1994) 363-367
9. Kozubski, W., P. Sokolowski: Sodium valproate vs ergot derivatives in acute treatment of migraine attacks. Abstracts of the 10th Migraine Trust International Symposium. London, September 5-8, 1994
10. A receptors mediated effects of sodium valproate on durai plasma protein extravasation to substance P and trigeminal stimulation. British J. Pharmacol. 116 (1995) 1661-1667
11. A receptors located outside the blood brain barrier mediate Sodium valproate blockade of neurogenic and substance P-induced inflammation: possible mechanism in migraine. Cephalgia 15 (1995) Sup. 14, 102
12. Limmroth, V., F. M. Cutrer, M. A. Moskowitz: The role of neurotransmitters and neuropeptides in headache. Current Opin. Neurol. 9 (1996) 206-210
13. Lindhout, D., D. Schmidt: In-utero exposure to valproate and neural tube defects. Lancet II (1986) 1392-1393
14. Lindhout, D., J. G. C. Omtzigt: Teratogenic effects on antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia 35, Suppl. 4 (1994) S19-S28
15. Löscher, W.: Valproate induced changes in GABA metabolism at the subcellular level. Biochem. Pharmacol. 30 (1981) 1364-1366
16. Löscher, W.: Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem.-Res. 18 (1993) 485-502
17. Mathew, N. T., J. R. Saper, S. D. Silberstein et al.: Migraine prophylaxis with divalproex. Arch. Neurol. 52 (1995) 281-286
18. Pinder, R. M., R. N. Brogden, T. M. Speight et al.: Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs 13 (1977) 81-123
19. Sorensen, K. V.: Valproate: a new drug in migraine prophylaxis. Acta Neurol. Scand. 78 (1988) 346-348